

IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE

CEPHALON, INC.,)

)
)
Plaintiff,)

)
v.)

)
SANDOZ INC.; ACCORD HEALTHCARE,)
INC.; INTAS PHARMACEUTICALS LTD.;)
INNOPHARMA, INC.; AGILA)
SPECIALTIES INC. f/k/a STRIDES, INC.;)
ONCO THERAPIES LIMITED; GLENMARK)
PHARMACEUTICALS LTD.; GLENMARK)
GENERICS LTD.; GLENMARK GENERICS)
S.A.; GLENMARK GENERICS INC., USA;)
EUROHEALTH INTERNATIONAL SARL;)
and WEST-WARD PHARMACEUTICAL)
CORP.,)

)
Defendants.)
_____)

C.A. No. _____

**AMENDED SUPPLEMENTAL INFORMATION FOR PATENT CASES INVOLVING
AN ABBREVIATED NEW DRUG APPLICATION (ANDA)**

Plaintiff(s) hereby provide(s) the information below with respect to the deadlines set forth in 21 U.S.C. 355(j):

Date Patentee(s) Received Notice: _____

Date of Expiration of the U.S. Patent 8,883,836: March 26, 2029

Thirty Month Stay Deadline:¹ _____

February 23, 2015
Date

/s/Stephen Brauerman
Attorney(s) for Plaintiff

¹ No thirty-month stay is associated with this action. However, there is a thirty-month stay associated with the co-pending related action filed by Plaintiff Cephalon, Inc. *In re: Bendamustine Consolidated Cases*, Civil Action No. 13-2046-GMS (consolidated).